SCHEMBL2889129

SCHEMBL2889129

NC(=O)c1cc([N+](=O)[O-])cc([N+](=O)[O-])c1Cl

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.68
LMNA P02545 2/20 0.68
SMN1; SMN2 Q16637 2/20 0.55
CYP3A4 P08684 1/20 0.55
KMT2A Q03164 5/20 0.54
NPSR1 Q6W5P4 3/20 0.51
HTT P42858 3/20 0.51
MAPT P10636 2/20 0.51
MITF O75030 1/20 0.51
CCR6 P51684 1/20 0.51
GPR35 Q9HC97 4/20 0.50
CASP1 P29466 1/20 0.48
TSHR P16473 2/20 0.46
MEN1 O00255 3/20 0.45
HPGD P15428 3/20 0.45
KDM4E B2RXH2 1/20 0.44
TTR P02766 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
ALOX15 P16050 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetonitrile SCHEMBL27886067 0.91 ALDH1A1 (0.57) ALDH1A1LMNASMN1; SMN2CYP3A4KMT2A
SCHEMBL1487913 0.84 CA1 (0.53) ALDH1A1LMNACYP3A4KMT2ANPSR1
SCHEMBL2961900 0.84 ALDH1A1 (0.51) ALDH1A1LMNASMN1; SMN2CYP3A4KMT2A
SCHEMBL6121980 0.84 ALDH1A1 (0.47) ALDH1A1LMNASMN1; SMN2CYP3A4KMT2A
SCHEMBL10483657 0.83 ALDH1A1 (0.50) ALDH1A1LMNASMN1; SMN2CYP3A4KMT2A
Hydrochloric Acid SCHEMBL2961904 0.83 CA1 (0.51) ALDH1A1LMNACYP3A4KMT2ANPSR1
SCHEMBL28312516 0.83 ALDH1A1 (0.54) ALDH1A1LMNASMN1; SMN2CYP3A4KMT2A
SCHEMBL10563402 0.83 ALDH1A1 (0.50) ALDH1A1LMNASMN1; SMN2CYP3A4KMT2A
SCHEMBL3686974 0.81 ALDH1A1 (1.00) ALDH1A1LMNASMN1; SMN2CYP3A4KMT2A
SCHEMBL29711645 0.81 ALDH1A1 (1.00) ALDH1A1LMNASMN1; SMN2CYP3A4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102659616-B Pre-column derivatization reagent and preparation process HUBEI YUANDA FUCHI PHARMACEUTICAL CHEMICALS CO LTD 2014-03-26 CN disclosed
US-8440842-B2 Antimicrobial compounds, their synthesis and their use for treatment of mammalian infections LEIBNIZ-INSTITUT FUER NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE E.V. HANS-KNOELL-INSTITUT (DE) 2013-05-14 US disclosed
CN-102659616-A Pre-column derivatization reagent and preparation process HUBEI YUANDA FUCHI PHARMACEUTICAL CHEMICALS CO LTD 2012-09-12 CN disclosed
US-20100286130-A1 ANTIMICROBIAL COMPOUNDS, THEIR SYNTHESIS AND THEIR USE FOR TREATMENT OF MAMMALIAN INFECTIONS LEIBNIZ-INSTITUT FUER NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE E.V. HANS-KNOELL-INSTITUT (DE) 2010-11-11 US disclosed
EP-2176248-B1 NEW ANTIMICROBIAL COMPOUNDS, THEIR SYNTHESIS AND THEIR USE FOR TREATMENT OF MAMMALIAN INFECTIONS LEIBNIZ INST NATURSTOFF FORSCH (DE) 2010-09-29 EP disclosed
US-20100121091-A1 Processes of preparing asymmetric dinitrobenzamide mustard compounds, intermediate compounds useful therein and products obtained therefrom AUCKLAND UNISERVICES LIMITED (NZ) 2010-05-13 US disclosed
US-20100121091-A1 Processes of preparing asymmetric dinitrobenzamide mustard compounds, intermediate compounds useful therein and products obtained therefrom AUCKLAND UNISERVICES LIMITED (NZ) 2010-05-13 US disclosed
US-20100121091-A1 Processes of preparing asymmetric dinitrobenzamide mustard compounds, intermediate compounds useful therein and products obtained therefrom AUCKLAND UNISERVICES LIMITED (NZ) 2010-05-13 US disclosed
EP-2176248-A1 NEW ANTIMICROBIAL COMPOUNDS, THEIR SYNTHESIS AND THEIR USE FOR TREATMENT OF MAMMALIAN INFECTIONS Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. Hans-Knöll-Institut (DE) 2010-04-21 EP disclosed
EP-2059499-A1 PROCESSES OF PREPARING ASYMMETRIC DINITROBENZAMIDE MUSTARD COMPOUNDS, INTERMEDIATE COMPOUNDS USEFUL THEREIN AND PRODUCTS OBTAINED THEREFROM Auckland Uniservices Limited (NZ) 2009-05-20 EP disclosed
EP-1312607-A1 Dithiocarbamate derivatives and their use as antibacterial agents MEDAC GmbH (DE) 2003-05-21 EP disclosed
US-6517836-B1 Aziridin-1-yl nitrobenzamides as prodrugs in conjunction with nitroreductase enzymes AUCKLAND UNISERVICES LIMITED (NZ) 2003-02-11 US disclosed
EP-1109550-A2 NOVEL NITROPHENYLAZIRIDINE COMPOUNDS AND THEIR USE AS PRODRUGS CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) 2001-06-27 EP disclosed
WO-2000013683-A2 NOVEL NITROPHENYLAZIRIDINE COMPOUNDS AND THEIR USE AS PRODRUGS CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) 2000-03-16 WO disclosed
US-4281151-A ANTIALLERGENS, ANTIANAPHYLACTIC AGENTS THE UPJOHN COMPANY (US) 1981-07-28 US disclosed
US-4186127-A ANTIALLERGENS THE UPJOHN COMPANY (US) 1980-01-29 US disclosed
US-4159278-A PROPHYAXIS, ANTIALLERGENS, SENSITIZATION THE UPJOHN COMPANY (US) 1979-06-26 US disclosed
US-4095028-A PROPHYLAXIS, ALLERGIES THE UPJOHN COMPANY (US) 1978-06-13 US disclosed
US-4089973-A Cyano phenylene dioxamic acid compounds used in the treatment of allergy THE UPJOHN COMPANY (US) 1978-05-16 US disclosed
US-3993679-A ANTIALLERGY THE UPJOHN COMPANY (US) 1976-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100121091-A1 Processes of preparing asymmetric dinitrobenzamide mustard compounds, intermediate compounds useful therein and products obtained therefrom HRH2, HRH4, H1-2 ALDH1A1 343/4885LMNA 3821/4885SMN1; SMN2 2823/4885
US-20100286130-A1 ANTIMICROBIAL COMPOUNDS, THEIR SYNTHESIS AND THEIR USE FOR TREATMENT OF MAMMALIAN INFECTIONS ARG1, ARG2, LPO ALDH1A1 821/4885LMNA 2186/4885SMN1; SMN2 3419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.